4-Methylmorpholine → (E)-4-[2-(1H-indazol-3-yl)vinyl]-N-(piperidin-4-yl)benzamide dihydrochloride

온도

60 °C

The product obtained using (E)-4-[2-(1H-indazol-3-yl)vinyl]benzoic acid (500 mg, 1.66 mmol) obtained in Step 6 of Example 1, 1-tert-butoxycarbonyl-4-aminopiperidine (500 mg, 2.49 mmol), 1-hydroxybenzotriazole monohydrate (291 mg, 2.16 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (450 mg, 2.32 mmol) and N-methylmorpholine (0.37 mL, 3.32 mmol) in a similar manner to Example 5, was dissolved in methanol (2.00 mL), and the solution was added with 4 mol/L hydrogen chloride-methanol solution (1.50 mL), followed by heating under reflux at 60° C. for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the residue was crystallized from acetone to obtain Compound 120 (337 mg, 48%).

1. customThe product obtained
2. temperatureby heating
3. concentrationThe reaction mixture was concentrated under reduced pressure
4. customthe residue was crystallized from acetone

ORD 기록

ord-64b6c6bc0e0f4efabd2d21738b55a2c5

출처 데이터셋

uspto-grants-2011_04

DOI

10.6084/m9.figshare.5104873.v1

특허 번호

US07919517B2